FibroBiologics Statistics
Total Valuation
FibroBiologics has a market cap or net worth of $34.95 million. The enterprise value is $33.40 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, after market close.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
FibroBiologics has 38.26 million shares outstanding. The number of shares has increased by 18.32% in one year.
Current Share Class | 38.26M |
Shares Outstanding | 38.26M |
Shares Change (YoY) | +18.32% |
Shares Change (QoQ) | +7.46% |
Owned by Insiders (%) | 20.04% |
Owned by Institutions (%) | 16.86% |
Float | 28.46M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 14.67 |
P/TBV Ratio | 14.87 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 3.03.
Current Ratio | 1.14 |
Quick Ratio | 1.06 |
Debt / Equity | 3.03 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -926.13 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -81.15% |
Return on Invested Capital (ROIC) | -240.21% |
Return on Capital Employed (ROCE) | -460.90% |
Revenue Per Employee | n/a |
Profits Per Employee | -$589,769 |
Employee Count | 13 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.95% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -91.95% |
50-Day Moving Average | 1.00 |
200-Day Moving Average | 1.96 |
Relative Strength Index (RSI) | 45.72 |
Average Volume (20 Days) | 185,546 |
Short Selling Information
The latest short interest is 1.59 million, so 4.15% of the outstanding shares have been sold short.
Short Interest | 1.59M |
Short Previous Month | 1.53M |
Short % of Shares Out | 4.15% |
Short % of Float | 5.59% |
Short Ratio (days to cover) | 6.34 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -14.82M |
Pretax Income | -19.47M |
Net Income | -7.67M |
EBITDA | -14.64M |
EBIT | -14.82M |
Earnings Per Share (EPS) | -$0.22 |
Full Income Statement Balance Sheet
The company has $8.67 million in cash and $7.12 million in debt, giving a net cash position of $1.55 million or $0.04 per share.
Cash & Cash Equivalents | 8.67M |
Total Debt | 7.12M |
Net Cash | 1.55M |
Net Cash Per Share | $0.04 |
Equity (Book Value) | 2.35M |
Book Value Per Share | 0.06 |
Working Capital | 1.12M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$12.90 million and capital expenditures -$219,000, giving a free cash flow of -$13.12 million.
Operating Cash Flow | -12.90M |
Capital Expenditures | -219,000 |
Free Cash Flow | -13.12M |
FCF Per Share | -$0.34 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
FibroBiologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -18.32% |
Shareholder Yield | -18.32% |
Earnings Yield | -21.94% |
FCF Yield | -37.54% |
Analyst Forecast
The average price target for FibroBiologics is $13.00, which is 1,323.25% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $13.00 |
Price Target Difference | 1,323.25% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | 11.55% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |